Please ensure Javascript is enabled for purposes of website accessibility
Inicio > Productos > Anticuerpos > Biosimilares

Anti-Human CD43 Reference Antibody (Leukotuximab, RUO) (HB263016)

Anti-Human CD43 Reference Antibody (Leukotuximab, RUO)
Anti-Human CD43 Reference Antibody (Leukotuximab, RUO)
Precio(USD):
Especificación:
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
Número:
Contáctenos
  • Vista general

  • Imágenes

  • Referencias

  • Datasheet

  • SDS

Vista general
Número de catálogoHB263016
Descripción
Leukotuximab (HB263016) is a research-grade recombinant antibody targeting CD43. Produced in mammalian cells with native-like glycosylation.
Highlights
  • ●Research Grade — For PK/PD studies, assay development, and ADA research.
  • ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactividad de especiesHuman
AplicacionesELISA, Bioactivity: FACS, Functional assay, Research in vivo
Especie huéspedHuman
ClonalidadMonoclonal
IsotipoIgG1-kappa
Sistema de expresión Mammalian cells
Objetivo GPL115, Leukocyte sialoglycoprotein, Leukosialin, Sialophorin, SPN, Galactoglycoprotein, CD43, CD43ct, CD43-ct, GALGP
Nivel de endotoxinas < 10 EU/mg
Pureza >95% purity as determined by SDS-PAGE.
Purificación Protein A/G purified from cell culture supernatant.
Número de acceso P16150
Forma Liquid
Buffer de almacenamiento 0.01M PBS pH 7.4

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Estabilidad y almacenamiento Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativosAnti-JL1monoclonalantibody, ART-140, DNP-001, EGX-040, EGX-140, SSS-19
Fondo

Leukosialin (CD43/SPN) is a ~40 kDa protein. Predominant cell surface sialoprotein of leukocytes which regulates multiple T-cell functions, including T-cell activation, proliferation, differentiation, trafficking and migration. Positively regulates T-cell trafficking to lymph-nodes via its association with ERM proteins (EZR, RDX and MSN). Negatively regulates Th2 cell differentiation and predisposes the differentiation of T-cells towards a Th1 lineage commitment. Promotes the expression of IFN-gamma by T-cells during T-cell receptor (TCR) activation of naive cells and induces the expression of IFN-gamma by CD4(+) T-cells and to a lesser extent by CD8(+) T-cells. Plays a role in preparing T-cells for cytokine sensing and differentiation into effector cells by inducing the expression of cytokine receptors IFNGR and IL4R, promoting IFNGR and IL4R signaling and by mediating the clustering of IFNGR with TCR.

1. Ramírez-Pliego, O. et al. (2007) BMC immunology 8, 30. PMID: 18036228
2. Galindo-Albarrán, AO. et al. (2014) Journal of cellular physiology 229, 172-80. PMID: 24328034
Nota For research use only. Not suitable for clinical or therapeutic use.
Isotype Control Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)
Imágenes
  • Anti-Human CD43 Reference Antibody (Leukotuximab, RUO)

    SDS-PAGE

    SDS-PAGE for Research Grade Leukotuximab.

Referencias
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recomendación

Contáctenos para cotizaciones personalizadas, solicitudes en masa y cualquier otro problema.

Correo: [email protected]

Lista de distribuidores